Antipsychotics - Articles - Page 8

Is Clozapine the Next Step After a Single Failed Antipsychotic Trial?

November 1, 2018

Xavier Preud’homme, MD Dr. Preud’homme has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Clozapine is often used as a last resort in schizophrenia, even though practice guidelines recommend a trial of this medication after failing 2 antipsychotics. The current study set out to test a treatment algorithm based on those guidelines in patients with first-episode psychosis.

Antipsychotics and Aggressive Children With ADHD

July 12, 2018

The TOSCA study focused on children with severe ADHD, who also met criteria for oppositional defiant disorder (ODD) or conduct disorder (CD). These children tend not to do as well with stimulants alone and often end up being prescribed antipsychotics, typically second generation antipsychotics (SGA’s). TOSCA was devised to help...

Dose Maintenance, Reduction With Antipsychotics

June 1, 2018

Adam Strassberg, MD.

Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Once patients with schizophrenia are stabilized on an antipsychotic in the acute phase of their treatment, guidelines are unclear on how to continue dosing. Some guidelines recommend lowering the dose, others recommend maintaining the dose, and others give no firm recommendations whatsoever.

Lithium Favored in Treatment Effectiveness Study

June 1, 2018

Adam Strassberg, MD.

Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A new study from Finland shows that lithium may be more effective than other treatments in reducing the risk of psychiatric rehospitalization in patients with bipolar disorder.

Metformin to Control Antipsychotic-Induced Weight Gain in Children

May 1, 2018

Adam Strassberg, MD

Adam Strassberg, MD Psychiatrist in private practice in Palo Alto, CA. Contributing writer to the Carlat Report newsletters. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Metformin has been used off-label for weight loss in psychiatry for many years, much of it for help with adult weight gain as a side effect of atypical antipsychotics. However, most trials of metformin for weight loss were actually conducted on the child and adolescent population. This article will look at the quality of the data in our pediatric population of 3 studies, and then come up with some recommendations for your practice.

Note From the Editor-in-Chief

March 1, 2018

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, The Carlat Psychiatry Report

We publish an issue on antipsychotics at least once a year, and it’s always a challenge to decide what to cover. There are dozens of antipsychotics, and most of them are approved for mood disorders as well as psychosis.

Clozapine: A Fresh Look

March 1, 2018

For those reluctant to make clozapine their go-to antipsychotic for certain patients, this article will provide information to help you decide when it’s right to prescribe.

Abilify MyCite: Patient Care Breakthrough or Patent Extender?

March 1, 2018

You’ve probably heard about a new “digital pill” called Abilify MyCite. The product, which was FDA approved in November 2017, is the first drug in the U.S. with a digital ingestion tracking system.

Prescribing and Managing Antipsychotics

March 1, 2018

Thomas Schwartz, MD

Thomas Schwartz, MD.
Professor and Interim Chair of Psychiatry and Behavioral Sciences, Upstate Medical University, Syracuse, NY. Dr. Schwartz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

For those reluctant to make clozapine their go-to antipsychotic for certain patients, this article will provide information to help you decide when it’s right to prescribe.

Estrogen Modulator Raloxifene Not Helpful for Schizophrenic Women

January 1, 2018

Robert T. Rubin, MD

Robert T. Rubin, MD Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Since estrogen can affect neurotransmitter functioning, there has been some interest in using estrogen modulators to treat psychiatric conditions, including schizophrenia. Raloxifene is a selective estrogen receptor modulator (SERM) with some preliminary evidence for effectiveness in women with schizophrenia.